Update in Osteoporosis and Metabolic Bone Disorders
نویسندگان
چکیده
منابع مشابه
Update in osteoporosis and metabolic bone disorders.
Considerable progress has been made in the development and testing of agents to treat osteoporosis. Most impressive are reports on new antiresorptive agents--both bisphosphonates (ibandronate and zoledronic acid) and monoclonal antibodies (MAbs) (denosumab) directed against receptor activator of nuclear factor kappaB-ligand, a key molecule in the control of commitment and activation of osteocla...
متن کاملOsteoporosis in mineral and bone disorders of chronic kidney disease.
Osteoporosis is one of the epidemics in modern aging societies. Epidemiological studies indicate that many patients with osteoporosis are also characterized by diminished glomerular filtration rate (GFR), which indicates various degrees of chronic kidney disease (CKD). On the other hand, the status of osteoporosis in the classification of mineral and bone disorders in CKD has not been well defi...
متن کامل8: Disorders of bone and mineral other than osteoporosis.
Rickets in children and osteomalacia in adults are caused by undermineralisation of bone, which increases its susceptibility to bending and fracture; treatment is with calcium, vitamin D or phosphate, depending on the specific mineral or vitamin deficiency. In Paget's disease, osteoclasts are overactive and produce woven or "repair" bone, which is mechanically weaker than lamellar bone; treatme...
متن کاملSecondary Osteoporosis: Endocrine and Metabolic Causes of Bone Mass Deterioration
Secondary osteoporosis results from medical conditions or treatments that interfere with the attainment of peak bone mass and/or may predispose to accelerated bone loss. Although secondary osteoporosis is less common, it is becoming more frequently diagnosed. Apart from the well-defined risk of secondary osteoporosis in patients requiring long-term corticosteroids therapy, an increasing list of...
متن کاملOsteoporosis update from the 2012 Santa Fe Bone Symposium.
The core of the 2012 Santa Fe Bone Symposium consisted of plenary presentations on new developments in the fields of osteoporosis and metabolic bone disease, with a focus on current and future implications for patient care. These were complemented by oral abstracts, interactive discussions of challenging cases, a debate on benefits and risks of long-term bisphosphonate therapy, and a panel disc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Endocrinology & Metabolism
سال: 2007
ISSN: 0021-972X,1945-7197
DOI: 10.1210/jc.2007-0042